Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis

References

• Wendling D, Claudepierre P, Prati C, et al. Spondyloarthritis: a concept or a disease? Joint Bone Spine. 2015 Dec;82(6):387–389.
   PubMed Web of Science ®Google Scholar
• Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017 Jul 1;390(10089):73–84.
   PubMed Web of Science ®Google Scholar
• Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016 Jun 30; 374(26):2563–2574.
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009 Jun;68(Suppl. 2):ii1–44.
   PubMed Web of Science ®Google Scholar
• Claudepierre P, Wendling D, Breban M, et al. Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what’s in a name? Joint Bone Spine. 2012 Dec;79(6):534–535.
   PubMed Web of Science ®Google Scholar
• Moltó A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis. 2016 Jun;75(6):1016–1023.
   PubMed Web of Science ®Google Scholar
• Wendling D. Involvement of Th 17 pathway in spondyloarthritis. Bull Acad Natl Med. 2015 Oct;199(7):1177–1185.
   PubMed Web of Science ®Google Scholar
• Taams LS, Steel KJA, Srenathan U, et al. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14:453–466. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Chyuan IT, Chen JY. Role of interleukin- (IL-) 17 in the pathogenesis and targeted therapies in spondyloarthropathies. Mediators Inflamm. 2018 Feb 12;2018:2403935. eCollection 2018.
   PubMed Web of Science ®Google Scholar
• Miossec P. Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. RMD Open. 2017 Feb 15;3(1):e000284. eCollection 2017.
   PubMed Web of Science ®Google Scholar
• Wendling D, Guillot X, Prati C. The IL-23/Th17 pathway in spondyloarthritis: the royal road? Joint Bone Spine. 2015;82:1–4.
   PubMed Web of Science ®Google Scholar
• Wendling D, Cedoz JP, Racadot E, et al. Serum IL-17, BMP-7 and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74:304–305.
   PubMed Web of Science ®Google Scholar
• Jansen DT, Hameetman M, van Bergen J, et al. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. Rheumatology (Oxford). 2015 Apr;54(4):728–735.
   PubMed Web of Science ®Google Scholar
• Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011;13:R95.
   PubMed Web of Science ®Google Scholar
• Chen WS, Chang YS, Lin KC, et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc. 2012;75:303–308.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012 Jul 1;18(7):1069–1076.
   PubMed Web of Science ®Google Scholar
• Glatigny S, Fert I, Blaton MA, et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum. 2012;64:110–120.
   PubMedGoogle Scholar
• Wendling D. The gut in spondyloarthritis. Joint Bone Spine. 2016 Jul;83(4):401–405.
   PubMed Web of Science ®Google Scholar
• Wendling D, Prati C. Spondyloarthritis: an expanding cast of cellular actors. Joint Bone Spine. 2018 Jan;85(1):1–3.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74(9):1739–1747.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Res Ther. 2017 Mar 8;19(1):51.
   PubMedGoogle Scholar
• Wendling D. Interleukin-17 targeted therapies in axial spondyloarthritis. Immunotherapy. 2015;7(11):1125–1128.
   PubMed Web of Science ®Google Scholar
• Wendling D. An overview of investigational new drugs for treating ankylosing spondylitis. Expert Opin Invest Drugs. 2016;25(1):95–104.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Kiltz U. Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opin Biol Ther. 2016;16(5):711–722.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Nov 23;382(9906):1705–1713.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016 Feb;75(2):408–412.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534–2548.
   PubMed Web of Science ®Google Scholar
• Deodhar AA, Dougados M, Baeten DL, et al. Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase iii randomized trial (MEASURE 1). Arthritis Rheumatol. 2016 Dec;68(12):2901–2910.
   PubMed Web of Science ®Google Scholar
• Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis. 2017 Mar;76(3):571–592.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017 Jun;76(6):1070–1077.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Kivitz AJ, Deodhar AA, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018 Jan-Feb;36(1):50–55.
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1020–1029.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Conaghan P, Kvien T, et al. Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumor necrosis factor inhibitor therapy: 2-year data from MEASURE 2 study. Clin Exp Rheumatol. 2018. on line. [Epub ahead of print].
   Web of Science ®Google Scholar
• Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open. 2017 Dec 28;3(2):e000592.
   PubMed Web of Science ®Google Scholar
• Wei JC, Baeten D, Sieper J, et al. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies. Int J Rheum Dis. 2017 May;20(5):589–596.
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017 Dec 22;19(1):285.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Wagner U, Dokoupilova E, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther. 2018 Aug 18. Epub ahead of print. doi:10.1007/s40744-018-0123-5
   Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017 Nov 1;56(11):1993–2003.
   PubMed Web of Science ®Google Scholar
• Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018 Jun;77(6):890–897.
   PubMed Web of Science ®Google Scholar
• van Mens LJJ, van de Sande MGH, Menegatti S, et al. IL-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses. Arthritis Rheumatol. 2018 Jun 5. [ Epub ahead of print]. doi:10.1002/art.40581
   Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013 Apr;120(4):777–787.
   PubMed Web of Science ®Google Scholar
• Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015 May;122(5):939–948. Epub 2015 Jan 29. PubMed PMID: 25638011.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Miceli-Richard C, Baraliakos X, et al. Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis (abstract SAT0270). Ann Rheum Dis. 2018;77(Suppl. 2):999.
   Google Scholar
• Rothstein B, Gottlieb A. Secukinumab for treating plaque psoriasis. Expert Opin Biol Ther. 2016;16(1):119–128.
   PubMed Web of Science ®Google Scholar
• Abrouk M, Gandy J, Nakamura M, et al. Secukinumab in the treatment of psoriasis and psoriatic arthritis: a review of the literature. Skin Therapy Lett. 2017 Jul;22(4):1–6.
   PubMedGoogle Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693–1700.
   PubMed Web of Science ®Google Scholar
• Fobelo Lozano MJ, Serrano Giménez R, Castro Fernández M. Emergence of inflammatory bowel disease during treatment with secukinumab. J Crohns Colitis. 2018 May 9. Epub ahead of print PubMed PMID: 29746636. doi:10.1093/ecco-jcc/jjy063
   PubMed Web of Science ®Google Scholar
• Schreiber S, Sands B, Deodhar A, et al. No increased incidence of inflammatory bowel disease among secukinumab-treated patients with moderate to severe psoriasis, psoriatic arthritis, or ankylosing spondylitis: data from 14 phase 2 and phase 3 clinical studies. (Op0113). Ann Rheum Dis. 2016;75(Suppl. 2):97–98.
   Google Scholar
• Emery P, Van Keep M, Beard S, et al. Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Pharmacoeconomics. 2018 Aug;36(8):1015–1027.
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov secukinumab. [cited 2018 Nov 23]. Available from: https://clinicaltrials.gov/ct2/results?cond=spondyloarthritis&term=secukinumab&cntry=&state=&city=&dist=
   Google Scholar
• Mazurov V, Erdes S, Kunder E, et al. Efficacy and safety of Bcd-085, A novel Il-17 inhibitor, in ankylosing spondylitis. Results of phase 2 clinical study (OP0028). Ann Rheum Dis. 2018;77(Suppl. 2):64.
   Google Scholar
• Clinicaltrials.gov BCD085. [cited 2018 Nov 23]. Available from: https://clinicaltrials.gov/ct2/results?cond=spondyloarthritis&term=BCD-085&cntry=&state=&city=&dist=&Search=Search
   Google Scholar
• van der Heijde D, Gensler LS, Deodhar A, et al. Dual neutralisation of Il-17a and Il-17f with bimekizumab in patients with active ankylosing spondylitis (as): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study (LB001). Ann Rheum Dis. 2018;77(Suppl. 2):70.
   PubMedGoogle Scholar
• Clinicaltrials.gov Bimekizumab. [cited 2018 Nov 23]. Available from: https://clinicaltrials.gov/ct2/results?cond=spondyloarthritis&term=bimekizumab&cntry=&state=&city=&dist=&Search=Search
   Google Scholar
• Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016 Apr 19;9:39–50.
   PubMed Web of Science ®Google Scholar
• Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017 Jun 10;389(10086):2317–2327.
   PubMed Web of Science ®Google Scholar
• Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017 Jan;76(1):79–87.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov Ixekizumab. [cited 2018 Nov 23]. Available from: https://clinicaltrials.gov/ct2/results?cond=spondyloarthritis&term=ixekizumab&cntry=&state=&city=&dist=
   Google Scholar
• van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018 Oct 22:S0140–6736(18)31946–9. Epub ahead of print. doi:10.1016/S0140-6736(18)31946-9
   Web of Science ®Google Scholar
• Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: 16 week results of a phase 3 randomized, double-blind, placebo controlled trial in patients with prior inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2018 Oct 20. [ Epub ahead of print]. doi:10.1002/art.40753
   Google Scholar
• Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2018 Sep 18. [ Epub ahead of print] PubMed PMID: 3022599]. doi:10.1002/art.40728
   Web of Science ®Google Scholar
• Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018 Sep;77(9):1295–1302.
   PubMed Web of Science ®Google Scholar
• Gentileschi S, Vitale A, Rigante D, et al. prompt clinical response to secukinumab in patients with axial spondyloarthritis: real life observational data from three italian referral centers. Isr Med Assoc J. 2018 Jul;20(7):438–441.
   PubMed Web of Science ®Google Scholar
• Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann Rheum Dis. 2018 Oct 8. pii: annrheumdis-2018–213654. Epub ahead of print. doi:10.1136/annrheumdis-2018-213654
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Sieper J. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both? Rheumatology (Oxford). 2017 Oct 12. Epub ahead of print. doi:10.1093/rheumatology/kex361
   PubMedGoogle Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978–991.
   PubMed Web of Science ®Google Scholar
• Wendling D, Lukas C, Prati C, et al. 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. Joint Bone Spine. 2018 May;85(3):275–284.
   PubMed Web of Science ®Google Scholar